Retail sales fell sharply in May as consumers pulled back after a sharp increase in spending in March to get ahead of ...

Editas Medicine ( EDIT 12.04%) is a promising clinical-stage company that has captured Wall Street's attention at the ...

Drugmakers want more clarity from the Trump administration on the potential pharmaceutical tariffs, which some companies warn ...

Texas hemp users stockpile products and consider moving out of state as ban looms, saying the medical marijuana program is an ...

In March, the Food and Drug Administration approved Vykat XR, an extended-release version of the existing drug diazoxide choline, which eases the relentless hunger and may offer insights into the ...

Medicaid doesn’t need price controls from other countries; it already imposes them here. Under the program’s existing “Best ...

Eli Lilly's stock price has over-corrected following a downgrade in its outlook following the adjustment for acquisition ...

Pharmaceutical companies have little incentive to sell drugs to countries that can’t afford them. But bargaining together can ...

Some reasons for the tariffs include countering trade deficits to boosting domestic industries and pressuring foreign competitors.

Eli Lilly agreed to acquire Verve Therapeutics for approximately $1 billion up front, adding a potential treatment for cardiovascular disease to its portfolio.

Thailand’s pharmaceutical industry continues to face multiple challenges, particularly its heavy reliance on imported active ...

Organon faces profitability challenges and revenue declines. The valuation appears fair given the weak revenue outlook. See ...